NASDAQ:TCRX
TScan Therapeutics, Inc.
TScan Therapeutics, Inc.'s revenue grew 266.7% in fiscal 2025 to $10.3M while operating margin rose to −1315.4%. Free cash flow was −$139.7M, −1353.3% of revenue, and the diluted share count rose 15.9%.Summary generated from TScan Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 4, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$10.3M
Revenue growth+266.7%
Revenue, 5-yr CAGR+56.9%
Gross marginn/a
Operating margin−1315.4%
Net margin−1256.8%
ROIC−219.9%
Return on equity−71.3%
Debt / equity0.26
Free cash flow−$139.7M
FCF margin−1353.3%
Share count change+15.9%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 10 | 14 | 21 | 3 | 10 |
| Operating income | −49 | −67 | −93 | −135 | −136 |
| Net income | −49 | −66 | −89 | −127 | −130 |
| Free cash flow | −59 | −71 | −65 | −115 | −140 |
Recent filings
- 4Insider transaction report
Oct 2, 2026 - 4Insider transaction report
Oct 2, 2026 - 8-KDirector or officer change
Sep 30, 2026 - 8-KDirector or officer change
Sep 11, 2026 - 8-KCosts of exit or disposal activities
Sep 2, 2026 - 8-KTermination of a material agreement
Aug 18, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 12, 2026 - 8-KResults of operations and financial condition
Aug 12, 2026